The addition of PD-1/PD-L1 axis blockade to BRAF and MEK inhibition for advanced melanoma patients harboring BRAF mutations: a systematic review and meta-analysis

The addition of PD-1/PD-L1 axis blockade to BRAF and MEK inhibition for advanced melanoma patients harboring BRAF mutations: a systematic review and meta-analysis

Objectives: Immune-checkpoint inhibitors (ICI) and targeted-therapies (TT) have become standard options for BRAF-V600 metastatic melanomas (MM). Recently, randomized trials (RCT) addressed the efficacy of combined approaches, with conflicting results. We sought to evaluate efficacy and safety of fir...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Brazilian Journal of Oncology 2022-10, Vol.18
Hauptverfasser: Ribeiro, Mauricio Fernando Silva Almeida, Xavier, Camila Bragança, Pereira, Allan Andresson Lima, Scaranti, Mariana, Faria, Luiza Dib Batista Bugiato, Correa, Tatiana Strava, Sahade, Marina, Muniz, David Queiroz Borges, Feher, Olavo, Fernandes, Gustavo dos Santos, Katz, Artur, Munhoz, Rodrigo Ramella
Format: Artikel
Sprache:eng
Schlagworte:
immunotherapy
map kinase signaling system
melanoma
programmed cell death 1 receptor
proto-oncogene proteins b-raf
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Objectives: Immune-checkpoint inhibitors (ICI) and targeted-therapies (TT) have become standard options for BRAF-V600 metastatic melanomas (MM). Recently, randomized trials (RCT) addressed the efficacy of combined approaches, with conflicting results. We sought to evaluate efficacy and safety of first-line combination ICI and BRAF/MEK inhibitors (triplets) versus BRAF/MEKi (doublets). Methods: We performed a systematic review and metaanalysis of RCT comparing triplet versus doublet published in MEDLINE and EMBASE from 2016-September/2020. We obtained pooled effect estimates through random-effects model assuming p
ISSN:2526-8732
2526-8732
DOI:10.5935/2526-8732.20220298